GNMK GenMark Diagnostics, Inc.
3,439
$24.04
$0.00
(0.00%)
| Watchers | 3,439 |
| 52-Wk Low | $8.47 |
| 52-Wk High | $24.25 |
| Market Cap | $1.77B |
| Volume (M) | 3.83M |
| 52-Wk High | $24.25 |
| 52-Wk Low | $8.47 |
Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research(R)Globe Newswire • about 2 years ago
---
- Increasing numbers of company initiatives across the world coupled with the benefits
of gene panels are the major factors that help in fostering the gene panel market.
Moreover, increasing adoption of genetic testing, technological advancements such
as the Next Generation Sequencing System, and the ...
Share to Feed
---
- Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for
new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
- ''
- " Swiss pharma giant Roche Holding AGs RHHBY performance in the second quarter,
and consequently in the first half of 2021, gained ..."
---
- GenMark Diagnostics (NASDAQ:GNMK) and Pulmonx (NASDAQ:LUNG) are both small-cap medical
companies, but which is the superior investment? We will contrast the two companies
based on the strength of their dividends, analyst recommendations, earnings, institutional
ownership, valuation, profitability ...
---
- EMC Capital Management raised its holdings in shares of GenMark Diagnostics, Inc.
(NASDAQ:GNMK) by 8.9% in the first quarter, according to the company in its most
recent disclosure with the Securities and Exchange Commission. The fund owned 121,023
shares of the medical equipment providers stock ...
---
- Paradigm Capital Management Inc. NY boosted its stake in shares of GenMark Diagnostics,
Inc. (NASDAQ:GNMK) by 18.1% during the 1st quarter, Holdings Channel reports. The
institutional investor owned 733,300 shares of the medical equipment providers stock
after buying an additional 112,500 shares ...
---
- Chicago Capital Management LLC purchased a new position in GenMark Diagnostics,
Inc. (NASDAQ:GNMK) during the 1st quarter, according to its most recent disclosure
with the Securities and Exchange Commission (SEC). The institutional investor purchased
318,113 shares of the medical equipment providers...
---
- GenMark Diagnostics, Inc. (NASDAQ:GNMK) has earned a consensus recommendation of
Hold from the six brokerages that are covering the company, Marketbeat reports.
One research analyst has rated the stock with a sell rating and five have issued
a hold rating on the company. The average ...
---
- Motus GI (NASDAQ:MOTS) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap
medical companies, but which is the superior business? We will contrast the two
companies based on the strength of their valuation, earnings, profitability, dividends,
analyst recommendations, risk and institutional ...
---
- JPMorgan Chase Co. grew its holdings in shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK)
by 21.0% during the fourth quarter, according to the company in its most recent
Form 13F filing with the Securities and Exchange Commission. The fund owned 31,404
shares of the medical equipment provider...
---
- Motus GI (NASDAQ:MOTS) and GenMark Diagnostics (NASDAQ:GNMK) are both small-cap
medical companies, but which is the superior stock? We will compare the two businesses
based on the strength of their earnings, risk, valuation, profitability, dividends,
analyst recommendations and institutional ...
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
Latest GNMK News
Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research(R)
Globe Newswire • about 2 years ago
Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars
Zacks Investment Research • over 2 years ago
GenMark Diagnostics (NASDAQ:GNMK) & Pulmonx (NASDAQ:LUNG) Head to Head Comparison
Zolmax • over 2 years ago